Overview
BIVI market data
Price History
BIVI price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$11.87 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.64 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.82 – $2.31 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $8.3M · P/B 0.90.
Company News
BioVie Q4 EPS $(0.70) Up From $(1.42) YoYBenzinga · Aug 13, 2026, 10:29 AM
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · Aug 7, 2026, 5:05 PM
BioVie shares are trading lower. The company announced results from Phase 2 SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease.Benzinga · Aug 6, 2026, 5:34 PM
Nasdaq Down 50 Points; US Foods Posts Upbeat EarningsBenzinga · Aug 6, 2026, 1:43 PM
BioVie Says Phase 2 SUNRISE-PD Trial Of Bezisterim In Early Parkinson's Disease Met Prespecified Endpoints, Showing Statistically Significant Motor And Non-Motor Improvements vs. PlaceboBenzinga · Aug 6, 2026, 11:34 AM
Why Eva Live Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving PremarketBenzinga · Jul 20, 2026, 8:56 AM
BioVie Files Prospectus To Offer Up To $300M In SecuritiesBenzinga · Jun 18, 2026, 9:30 PM
BioVie Announces Full Enrollment Of ADDRESS-LC Phase 2 Trial Evaluating Drug Candidate Bezisterim For Treatment Of Neurological Symptoms Of Long COVIDBenzinga · May 26, 2026, 12:06 PM
BioVie Announces Completion Of Last Patient Evaluation Visit In The SUNRISE-PD Phase 2 Trial Evaluating Its Drug Candidate Bezisterim In Early Stage Parkinson's DiseaseBenzinga · May 18, 2026, 12:05 PM